Dates: February 14-16, 2019
 Paris, France
Chairs: H Einsele, C Chabannon
Co-chair: M Hudecek
With keynote lectures: Carl June, Michel Sadelain and Stanley Riddell

This meeting, first of its kind in Europe, is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).

The recent approval of the first CAR T cell treatments in Europe presents a great opportunity to fight hematological malignancies but also poses serious challenges given the peculiar nature of the treatment. Patients, physicians, nurses, hospitals and whole health systems need to learn how to select the right treatments, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T therapy.

This meeting provides the ideal context to meet these learning objectives, with speakers that will share first-hand experience, including presenters from the US that pioneered the field. The program will include a comprehensive outlook on the current research efforts to increase CAR T cell therapies efficacy and targets, with input from basic researchers as well as representatives from the industry.

Below you can find key information and links to important details regarding registration and accommodation. There is also a wide array of sponsorship opportunities available for pharmaceutical companies.